Abstract
Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome
Blood
11/15/2022
DOI: 10.1182/blood.2020008241
Abstract
Agents targeting the unique biology of mycosis fungoides and Sézary syndrome are quickly being incorporated into clinical management. With these new therapies, we are now capable of inducing more durable responses and even complete remissions in advanced disease, outcomes which were exceedingly rare with prior therapies. Yet, even this new generation of therapies typically produce objective responses in only a minority of patients. As our therapeutic options increase, we are now challenged with selecting treatments from a growing list of options. To gain the full benefit of these novel agents, we must develop strategies to match treatments for the patients most likely to benefit from them. Here, we consider both the current approaches to treatment selection based on clinical features and the future of molecular biomarker-guided therapy for patients with this heterogeneous disease.
Details
- Title: Subtitle
- Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome
- Creators
- Michael S. Khodadoust - Stanford UniversityEric Mou - University of IowaYoun H. Kim - Stanford University
- Resource Type
- Abstract
- Publication Details
- Blood
- DOI
- 10.1182/blood.2020008241
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 11/15/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363170602771
Metrics
14 Record Views